New Report Available: Oryzon Genomics S.A. - Product Pipeline Analysis, 2013 Update

From: Fast Market Research, Inc.
Published: Thu Aug 08 2013

Oryzon Genomics (Oryzon) is a biopharmaceutical company. It develops therapies and biological solutions for cancer and neurodegenerative diseases. The company specializes in the field of preventative medicine. It carries out its operations under three business units, namely, Diagnostics, Personalized Medicine and Therapy. The company's diagnostic products in pipeline include GynEC-DX for endometrial cancer; Cxbladder for bladder cancer; and ColoBRAF for colorectal cancer. It produces NCEs and monoclonal antibodies for Neurogeneration and Cancer. The company offers comprehensive range of services including genomics, development of accompanying markers for in vivo efficacy studies, target validation, development of new biochemical or cellular assays including cell panel testing, B2D2 Platform and bioinformatics. The company is certified as per ISO 9001 for quality system management. Oryzon is headquartered in Barcelona, Spain.

Full Report Details at

This report is a source for data, analysis and actionable intelligence on the Oryzon Genomics S.A. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.


* Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
* Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
* Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
* Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
* Data on relevant clinical trials and product patent details, wherever applicable.
* Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Get this Report

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Cepheid (CPHD) - Product Pipeline Analysis, 2013 Update
- FK-Biotecnologia SA - Product Pipeline Analysis, 2013 Update
- Oryzon Genomics - Product Pipeline Analysis
- GE Healthcare - Product Pipeline Analysis , 2013 Update
- Philips Healthcare - Product Pipeline Analysis, 2013 Update

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »